Search
Skip to Search Results- 2Field, Catherine J.
- 2Gänzle, Michael G.
- 2Sawyer, Michael B.
- 1Baracos, Vickie
- 1Baracos, Vickie E.
- 1Bibova, Ilona
-
2012
Ketabi, Ali, Baracos, Vickie E., Field, Catherine J., Lin, Xiaoxi, Xue, Hongyu, Bibova, Ilona, Gänzle, Michael G., Dieleman, Levinus A., Sawyer, Michael B.
Intestinal microbiota mediate toxicity of irinotecan (CPT-11) cancer therapies and cause systemic infection after CPT-11-induced loss of barrier function. The intestinal microbiota and their functions are thus potential targets for treatment to mitigate CPT-11 toxicity. However, microbiota...
-
2013
Ruth, Megan R., Field, Catherine J.
The intestine and the gut-associated lymphoid tissue (GALT) are essential components of whole body immune defense, protecting the body from foreign antigens and pathogens, while allowing tolerance to commensal bacteria and dietary antigens. The requirement for protein to support the immune system...
-
The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats
Download2014
Baracos, Vickie, Dieleman, Levinus, Farhangfar, Arazm, Lin, Xiaoxi B., Gänzle, Michael G., Sawyer, Michael B., Valcheva, Rosica, Schieber, Andreas
CPT-11 is a drug used as chemotherapy for colorectal cancer. CPT-11 causes toxic side-effects in patients. CPT-11 toxicity has been attributed to the activity of intestinal microbiota, however, intestinal microbiota may also have protective effects in CP!-11 chemotherapy. This study aimed to...